Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double-Masked, Placebo-Controlled Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops) Used Twice Daily (BID) in the Treatment of Acquired Blepharoptosis

NCT06514612 is registered in ClinicalTrials.gov with Santen SAS as lead sponsor.

NCT NCT06514612
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06514612 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double-Masked, Placebo-Controlled Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops) Used Twice Daily (BID) in the Treatment of Acquired Blepharoptosis
Lead sponsor
Santen SAS
Phase
Phase 3
Overall status
Recruiting
Start date
December 30, 2024
Completion date
August 1, 2026
Enrollment
234 (estimated)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

acquired blepharophimosis